Wolfgang Haas

Summary

Affiliation: Bausch and Lomb
Country: USA

Publications

  1. doi Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin
    Wolfgang Haas
    Bausch and Lomb, 1400 North Goodman St, Rochester, NY, 14609, USA
    Adv Ther 29:442-55. 2012
  2. doi Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study
    Wolfgang Haas
    Bausch and Lomb, Inc, Rochester, New York 14609, USA
    Am J Ophthalmol 152:567-574.e3. 2011
  3. pmc Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones
    Wolfgang Haas
    Department of Microbiology and Sterilization Sciences, Bausch Lomb, Inc, Rochester, NY, USA
    Clin Ophthalmol 7:821-30. 2013
  4. doi High proportion of nontypeable Streptococcus pneumoniae isolates among sporadic, nonoutbreak cases of bacterial conjunctivitis
    Wolfgang Haas
    Bausch and Lomb, Inc, Rochester, NY 14609, USA
    Curr Eye Res 36:1078-85. 2011
  5. pmc Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae
    Wolfgang Haas
    Bausch Lomb, Inc, Rochester, NY 14609, USA
    J Antimicrob Chemother 65:1441-7. 2010
  6. pmc Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria
    Wolfgang Haas
    Bausch and Lomb, Inc, 1400 N Goodman St, Rochester, NY 14609, USA
    Antimicrob Agents Chemother 53:3552-60. 2009
  7. doi In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride
    Wolfgang Haas
    Bausch and Lomb, Inc, Rochester, NY 14609, USA
    J Antimicrob Chemother 66:840-4. 2011
  8. doi Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis
    Marguerite B McDonald
    Corneal Specialist and Cataract and Refractive Surgery, Ophthalmic Consultants of Long Island, Lynbrook, NY, USA
    Ophthalmology 116:1615-1623.e1. 2009
  9. doi Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin
    Christine M Sanfilippo
    Bausch and Lomb, Inc, Rochester, N Y, USA
    Chemotherapy 57:363-71. 2011
  10. pmc Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
    Timothy W Morris
    Microbiology and Sterilization Sciences, Bausch and Lomb, Rochester, NY, USA
    Clin Ophthalmol 5:1359-67. 2011

Collaborators

Detail Information

Publications12

  1. doi Microbiological etiology and susceptibility of bacterial conjunctivitis isolates from clinical trials with ophthalmic, twice-daily besifloxacin
    Wolfgang Haas
    Bausch and Lomb, 1400 North Goodman St, Rochester, NY, 14609, USA
    Adv Ther 29:442-55. 2012
    ..Since the etiologic agent is rarely identified, it is important to monitor which bacteria cause conjunctivitis and determine their antibacterial resistance profiles...
  2. doi Monitoring antibiotic resistance in ocular microorganisms: results from the Antibiotic Resistance Monitoring in Ocular micRorganisms (ARMOR) 2009 surveillance study
    Wolfgang Haas
    Bausch and Lomb, Inc, Rochester, New York 14609, USA
    Am J Ophthalmol 152:567-574.e3. 2011
    ....
  3. pmc Contribution of the R8 substituent to the in vitro antibacterial potency of besifloxacin and comparator ophthalmic fluoroquinolones
    Wolfgang Haas
    Department of Microbiology and Sterilization Sciences, Bausch Lomb, Inc, Rochester, NY, USA
    Clin Ophthalmol 7:821-30. 2013
    ..This study was conducted to determine the contribution of the R7 and R8 substituent to fluoroquinolone antibacterial activity...
  4. doi High proportion of nontypeable Streptococcus pneumoniae isolates among sporadic, nonoutbreak cases of bacterial conjunctivitis
    Wolfgang Haas
    Bausch and Lomb, Inc, Rochester, NY 14609, USA
    Curr Eye Res 36:1078-85. 2011
    ..This hypothesis was tested for 302 strains isolated during three prospective, multicenter clinical studies of bacterial conjunctivitis...
  5. pmc Bactericidal activity of besifloxacin against staphylococci, Streptococcus pneumoniae and Haemophilus influenzae
    Wolfgang Haas
    Bausch Lomb, Inc, Rochester, NY 14609, USA
    J Antimicrob Chemother 65:1441-7. 2010
    ..Here, the bactericidal activity of besifloxacin was evaluated against the most common bacterial conjunctivitis pathogens...
  6. pmc Besifloxacin, a novel fluoroquinolone, has broad-spectrum in vitro activity against aerobic and anaerobic bacteria
    Wolfgang Haas
    Bausch and Lomb, Inc, 1400 N Goodman St, Rochester, NY 14609, USA
    Antimicrob Agents Chemother 53:3552-60. 2009
    ..Besifloxacin demonstrated potent, broad-spectrum activity, which was particularly notable against gram-positive and gram-negative isolates that were resistant to other fluoroquinolones and classes of antibacterial agents...
  7. doi In vitro time-kill experiments with besifloxacin, moxifloxacin and gatifloxacin in the absence and presence of benzalkonium chloride
    Wolfgang Haas
    Bausch and Lomb, Inc, Rochester, NY 14609, USA
    J Antimicrob Chemother 66:840-4. 2011
    ..To compare the bactericidal activity of besifloxacin, moxifloxacin and gatifloxacin and determine the contribution of the preservative benzalkonium chloride (BAK) to bactericidal activity...
  8. doi Efficacy and safety of besifloxacin ophthalmic suspension 0.6% compared with moxifloxacin ophthalmic solution 0.5% for treating bacterial conjunctivitis
    Marguerite B McDonald
    Corneal Specialist and Cataract and Refractive Surgery, Ophthalmic Consultants of Long Island, Lynbrook, NY, USA
    Ophthalmology 116:1615-1623.e1. 2009
    ..To compare the clinical and antimicrobial efficacy of besifloxacin ophthalmic suspension 0.6% with that of moxifloxacin ophthalmic solution 0.5% for the treatment of bacterial conjunctivitis...
  9. doi Topoisomerase mutations that are associated with high-level resistance to earlier fluoroquinolones in Staphylococcus aureus have less effect on the antibacterial activity of besifloxacin
    Christine M Sanfilippo
    Bausch and Lomb, Inc, Rochester, N Y, USA
    Chemotherapy 57:363-71. 2011
    ....
  10. pmc Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
    Timothy W Morris
    Microbiology and Sterilization Sciences, Bausch and Lomb, Rochester, NY, USA
    Clin Ophthalmol 5:1359-67. 2011
    ..6%, administered three times a day (TID) for 5 days, integrated across three clinical trials of bacterial conjunctivitis and to investigate any microbiological eradication failures...
  11. pmc Molecular epidemiology of methicillin-resistant and methicillin-susceptible Staphylococcus aureus isolated from the eye
    Christine K Hesje
    Bausch and Lomb, Inc, Rochester, New York, USA
    Curr Eye Res 36:94-102. 2011
    ..This study determined the presence of traits characteristic for CA and HA strains in ocular MRSA isolates...
  12. pmc Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: etiology of bacterial conjunctivitis and antibacterial susceptibility profile
    Wolfgang Haas
    Microbiology and Sterilization Sciences, Bausch and Lomb Inc, Rochester, NY, USA
    Clin Ophthalmol 5:1369-79. 2011
    ..6%, and their in vitro antibacterial susceptibility profiles...